Biosynthetic Technologies
About Biosynthetic Technologies
Biosynthetic Technologies is a Healthcare company based in Indianapolis (United States) founded in 2012, and was acquired by Calumet Specialty Products Partners in April 2018. Producer of bio-based green oils. Biosynthetic Technologies has raised $52.24 million across 8 funding rounds from investors including bp, Monsanto and The Heritage Group. Biosynthetic Technologies has completed 1 acquisition, including Innoleo. Its chief executive, as recorded, is Mark Miller. Biosynthetic Technologies offers products and services including Estolides, BioEstolides, and Industrial Lubricants. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is BIOSYNTHETIC TECHNOLOGIES, LLC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Manufacturer of bio-based green oils. They produce synthetic oils, called estolides, from organic fatty acids found in various bio-derived oils. These are bio-degradable non-toxic and can be used as the primary base oil of a lubricant formulation, a component of a base oil co-blend, or as an additive. These oils have applications in many industries, such as cosmetic, chemicals, food-grade lubricants, car motor oil, and marine lubricant.
- Headquarters Indianapolis, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biosynthetic.com
- Social LinkedIn X Facebook YouTube
- Acquired by Calumet Specialty Products Partners (Apr 2018)
- Legal Name Biosynthetic Technologies, Llc
- Total Equity Funding$52.24M (USD)
in 8 rounds
- Latest Funding Round$9.5M (USD), Series A
May 2019
- Investorsbp
& 5 more
- Investments & Acquisitions
- Acquired byCalumet Specialty Products Partners
(Apr 2018)
Products & Services of Biosynthetic Technologies
Biosynthetic Technologies offers a comprehensive portfolio of products and services, including Estolides, BioEstolides, and Industrial Lubricants.
Sustainable compounds from bio-derived fatty acids for lubricant formulations.
Biodegradable oils for skincare and cosmetics applications.
High-performance oils for gear and hydraulic systems.
Apps and channels of Biosynthetic Technologies
its YouTube channel Biosynthetic Technologies has 59 subscribers and 29 videos.
Videos from Biosynthetic Technologies
The most watched videos on Biosynthetic Technologies's YouTube channel, Biosynthetic Technologies (59 subscribers). Click a video to play it here.
More on Biosynthetic Technologies.
Funding Insights of Biosynthetic Technologies
Biosynthetic Technologies has successfully raised a total of $52.24M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $9.5 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.24M
- Total Rounds 8
- Last Round Series A — $9.5M
- First Round $181,664
(Aug 2012)
- Investors Count 5
All 8 funding rounds of Biosynthetic Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $9.5M | Series A | – | The Heritage Group | – |
| Feb 2017 | $16.51M | Debt – Conventional | – | – | – |
| Oct 2014 | $12M | Series A | – | – | – |
| Jul 2014 | Series A | – | – | ||
| Aug 2013 | $9M | Series A | – | – | – |
| May 2013 | $14.74M | Series A | – | – | – |
| Nov 2012 | $7M | Series A | – | – | |
| Aug 2012 | $181,664 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Biosynthetic Technologies
Biosynthetic Technologies has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include bp, Monsanto and The Heritage Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A family-owned business managing diverse industrial and environmental companies. | thgrp.com | Indianapolis, United States | ||
Corporate venture capital investments are made by Evonik. | venturing.evonik.com | |||
bp is recognized as a global energy company. | 1909 | bp.com | United States | |
Genetically modified seeds and biotechnology traits are developed for farmers. | 1901 | monsanto.com | St. Louis, United States | |
Scientific and technical information is managed and disseminated by OSTI.GOV. | osti.gov | Oak Ridge, United States | ||
Calumet is engaged in manufacturing specialty products and renewable energy solutions. | calumetspecialty.com | Indianapolis, United States |
Investor details for Biosynthetic Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biosynthetic Technologies
8 people are tracked at Biosynthetic Technologies (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Mark Miller | CEO | Leadership |
Matt Kriech | Chief Executive Officer | Leadership |
Jeremy Forest | Chief, IP Counsel | Leadership |
Christian Crawford | Chief Commercial Officer | Leadership |
Alex Kitchel | Director Of Operations | Leadership |
Julie Austin | Research & Development Chemist | Team |
Jeffrey Mackey | Application & Commercialization Lead | Team |
Sylvain Maygnan | EMEA Salesmanager | Team |
Complete people profiles for Biosynthetic Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynthetic Technologies
Biosynthetic Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Innoleo.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Supplier & distributor of castor oil and derivatives of castor oil | innoleo.com | Macedonia, United States | 2011 | Jan 2022 | •••• |
Complete acquisition details for Biosynthetic Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biosynthetic Technologies
5 dated milestones of Biosynthetic Technologies across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Biosynthetic Technologies is founded.
- Funding First funding round of $182K.
- Exit Acquired by Calumet Specialty Products Partners.
- Funding Latest funding round, Series A, of $9.5M.
- Acquisition Acquires Innoleo.
Competitors of Biosynthetic Technologies
Biosynthetic Technologies has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Biosynthetic Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biosynthetic Technologies
The website of Biosynthetic Technologies (biosynthetic.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 104% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Biosynthetic Technologies (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biosynthetic Technologies
Complete news archive for Biosynthetic Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynthetic Technologies
Biosynthetic Technologies was founded in 2012.
Biosynthetic Technologies is headquartered in Indianapolis, United States. It is registered at Indianapolis, Indiana, United States.
Mark Miller is the CEO of Biosynthetic Technologies, as recorded in our data.
Biosynthetic Technologies is a funded company, having raised a total of $52.24M across 8 funding rounds to date. The company's 1st funding round was a Grant of $181.66K, raised on Aug 2012.
Manufacturer of bio-based green oils. They produce synthetic oils, called estolides, from organic fatty acids found in various bio-derived oils. These are bio-degradable non-toxic and can be used as the primary base oil of a lubricant formulation, a component of a base oil co-blend, or as an additive. These oils have applications in many industries, such as cosmetic, chemicals, food-grade lubricants, car motor oil, and marine lubricant.
Biosynthetic Technologies's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Biosynthetic Technologies offers Estolides, BioEstolides, and Industrial Lubricants.
Biosynthetic Technologies has made 1 acquisition, including Innoleo.
Biosynthetic Technologies has 6 investors. Key investors include bp, Monsanto, The Heritage Group, Evonik Venture Capital, and OSTI.GOV.
Biosynthetic Technologies operates through Biosynthetic Technologies, Llc.
Yes. Biosynthetic Technologies was acquired by Calumet Specialty Products Partners in April 2018.